EuroPharm Forum

The following links may be useful to you for clinical and professional practice purposes:

• Recommendations on extension of shelf life for Tamiflu
  (Source: European Medicines Agency)
  
  
• Adverse drug reactions: Neuraminidase inhibitors: widespread use for influenza may reveal more adverse effects
  (Source: The Pharmaceutical Journal)
  
  
• Oseltamivir (Tamiflu (R)) for the prevention and treatment of influenza during an influenza pandemic (Health Technology Assessment (HTA) Database)
  (Source: Centre for Reviews and Dissemination)
  
  
• Guidance on the use of zanamivir (Relenza) in the treatment of influenza (Health Technology Assessment (HTA) Database)
  (Source: Centre for Reviews and Dissemination)
  
  
• Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza: a systematic review and economic evaluation (NICE Technology Assessment Report (TAR))
  (Source: National Institute for Health Research)
  
  
• Oseltamivir, amantadine and zanamivir for the prophylaxis of influenza (including a review of TA67)
  (Source: National Institute for Health and Clinical Excellence)
  
  
• Amantadine, oseltamivir and zanamivir for the treatment of influenza (review of existing guidance No. 58)
  (Source: National Institute for Health and Clinical Excellence)
  
  
• Pharmacists key link in Dutch pandemic planning
  
  
  Back to Influenza A (H1N1) main page